Global Non-Hodgkin's Lymphoma Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 102

Published Date: 09 Jan 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Non-Hodgkin's lymphoma is a type of cancer that begins in your lymphatic system, which is part of the body's germ-fighting immune system. In non-Hodgkin's lymphoma, white blood cells called lymphocytes grow abnormally and can form growths (tumors) throughout the body.

According to our (Global Info Research) latest study, the global Non-Hodgkin's Lymphoma Drug market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Non-Hodgkin's Lymphoma Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Non-Hodgkin's Lymphoma Drug market size and forecasts, in consumption value ($ Million), 2018-2029
Global Non-Hodgkin's Lymphoma Drug market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Non-Hodgkin's Lymphoma Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Non-Hodgkin's Lymphoma Drug market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Non-Hodgkin's Lymphoma Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Non-Hodgkin's Lymphoma Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Gilead Sciences, TG Therapeutics, Bayer and Secura Bio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Non-Hodgkin's Lymphoma Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Oral
    Injection

Market segment by Application
    Hospital
    Retail Pharmacy
    Other

Market segment by players, this report covers
    Roche
    Gilead Sciences
    TG Therapeutics
    Bayer
    Secura Bio
    Epizyme
    Eisai
    Acrotech Biopharma
    Teva
    Eagle Pharmaceuticals
    MundiPharma

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Non-Hodgkin's Lymphoma Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Non-Hodgkin's Lymphoma Drug, with revenue, gross margin and global market share of Non-Hodgkin's Lymphoma Drug from 2018 to 2023.
Chapter 3, the Non-Hodgkin's Lymphoma Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Non-Hodgkin's Lymphoma Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Non-Hodgkin's Lymphoma Drug.
Chapter 13, to describe Non-Hodgkin's Lymphoma Drug research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Non-Hodgkin's Lymphoma Drug
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Non-Hodgkin's Lymphoma Drug by Type
        1.3.1 Overview: Global Non-Hodgkin's Lymphoma Drug Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type in 2022
        1.3.3 Oral
        1.3.4 Injection
    1.4 Global Non-Hodgkin's Lymphoma Drug Market by Application
        1.4.1 Overview: Global Non-Hodgkin's Lymphoma Drug Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Hospital
        1.4.3 Retail Pharmacy
        1.4.4 Other
    1.5 Global Non-Hodgkin's Lymphoma Drug Market Size & Forecast
    1.6 Global Non-Hodgkin's Lymphoma Drug Market Size and Forecast by Region
        1.6.1 Global Non-Hodgkin's Lymphoma Drug Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Non-Hodgkin's Lymphoma Drug Market Size by Region, (2018-2029)
        1.6.3 North America Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2018-2029)
        1.6.4 Europe Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2018-2029)
        1.6.6 South America Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Non-Hodgkin's Lymphoma Drug Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Roche
        2.1.1 Roche Details
        2.1.2 Roche Major Business
        2.1.3 Roche Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.1.4 Roche Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Roche Recent Developments and Future Plans
    2.2 Gilead Sciences
        2.2.1 Gilead Sciences Details
        2.2.2 Gilead Sciences Major Business
        2.2.3 Gilead Sciences Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.2.4 Gilead Sciences Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Gilead Sciences Recent Developments and Future Plans
    2.3 TG Therapeutics
        2.3.1 TG Therapeutics Details
        2.3.2 TG Therapeutics Major Business
        2.3.3 TG Therapeutics Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.3.4 TG Therapeutics Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 TG Therapeutics Recent Developments and Future Plans
    2.4 Bayer
        2.4.1 Bayer Details
        2.4.2 Bayer Major Business
        2.4.3 Bayer Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.4.4 Bayer Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Bayer Recent Developments and Future Plans
    2.5 Secura Bio
        2.5.1 Secura Bio Details
        2.5.2 Secura Bio Major Business
        2.5.3 Secura Bio Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.5.4 Secura Bio Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Secura Bio Recent Developments and Future Plans
    2.6 Epizyme
        2.6.1 Epizyme Details
        2.6.2 Epizyme Major Business
        2.6.3 Epizyme Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.6.4 Epizyme Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Epizyme Recent Developments and Future Plans
    2.7 Eisai
        2.7.1 Eisai Details
        2.7.2 Eisai Major Business
        2.7.3 Eisai Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.7.4 Eisai Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Eisai Recent Developments and Future Plans
    2.8 Acrotech Biopharma
        2.8.1 Acrotech Biopharma Details
        2.8.2 Acrotech Biopharma Major Business
        2.8.3 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.8.4 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Acrotech Biopharma Recent Developments and Future Plans
    2.9 Teva
        2.9.1 Teva Details
        2.9.2 Teva Major Business
        2.9.3 Teva Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.9.4 Teva Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Teva Recent Developments and Future Plans
    2.10 Eagle Pharmaceuticals
        2.10.1 Eagle Pharmaceuticals Details
        2.10.2 Eagle Pharmaceuticals Major Business
        2.10.3 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.10.4 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Eagle Pharmaceuticals Recent Developments and Future Plans
    2.11 MundiPharma
        2.11.1 MundiPharma Details
        2.11.2 MundiPharma Major Business
        2.11.3 MundiPharma Non-Hodgkin's Lymphoma Drug Product and Solutions
        2.11.4 MundiPharma Non-Hodgkin's Lymphoma Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 MundiPharma Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Non-Hodgkin's Lymphoma Drug Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Non-Hodgkin's Lymphoma Drug by Company Revenue
        3.2.2 Top 3 Non-Hodgkin's Lymphoma Drug Players Market Share in 2022
        3.2.3 Top 6 Non-Hodgkin's Lymphoma Drug Players Market Share in 2022
    3.3 Non-Hodgkin's Lymphoma Drug Market: Overall Company Footprint Analysis
        3.3.1 Non-Hodgkin's Lymphoma Drug Market: Region Footprint
        3.3.2 Non-Hodgkin's Lymphoma Drug Market: Company Product Type Footprint
        3.3.3 Non-Hodgkin's Lymphoma Drug Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Non-Hodgkin's Lymphoma Drug Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Non-Hodgkin's Lymphoma Drug Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2018-2023)
    5.2 Global Non-Hodgkin's Lymphoma Drug Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2029)
    6.2 North America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2029)
    6.3 North America Non-Hodgkin's Lymphoma Drug Market Size by Country
        6.3.1 North America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2018-2029)
        6.3.2 United States Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        6.3.3 Canada Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        6.3.4 Mexico Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2029)
    7.2 Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2029)
    7.3 Europe Non-Hodgkin's Lymphoma Drug Market Size by Country
        7.3.1 Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2018-2029)
        7.3.2 Germany Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        7.3.3 France Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        7.3.5 Russia Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        7.3.6 Italy Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size by Region
        8.3.1 Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2018-2029)
        8.3.2 China Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        8.3.3 Japan Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        8.3.4 South Korea Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        8.3.5 India Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        8.3.7 Australia Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2029)
    9.2 South America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2029)
    9.3 South America Non-Hodgkin's Lymphoma Drug Market Size by Country
        9.3.1 South America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2018-2029)
        9.3.2 Brazil Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        9.3.3 Argentina Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size by Country
        10.3.1 Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2018-2029)
        10.3.2 Turkey Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)
        10.3.4 UAE Non-Hodgkin's Lymphoma Drug Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Non-Hodgkin's Lymphoma Drug Market Drivers
    11.2 Non-Hodgkin's Lymphoma Drug Market Restraints
    11.3 Non-Hodgkin's Lymphoma Drug Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Non-Hodgkin's Lymphoma Drug Industry Chain
    12.2 Non-Hodgkin's Lymphoma Drug Upstream Analysis
    12.3 Non-Hodgkin's Lymphoma Drug Midstream Analysis
    12.4 Non-Hodgkin's Lymphoma Drug Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Roche Company Information, Head Office, and Major Competitors
    Table 6. Roche Major Business
    Table 7. Roche Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 8. Roche Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Roche Recent Developments and Future Plans
    Table 10. Gilead Sciences Company Information, Head Office, and Major Competitors
    Table 11. Gilead Sciences Major Business
    Table 12. Gilead Sciences Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 13. Gilead Sciences Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Gilead Sciences Recent Developments and Future Plans
    Table 15. TG Therapeutics Company Information, Head Office, and Major Competitors
    Table 16. TG Therapeutics Major Business
    Table 17. TG Therapeutics Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 18. TG Therapeutics Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. TG Therapeutics Recent Developments and Future Plans
    Table 20. Bayer Company Information, Head Office, and Major Competitors
    Table 21. Bayer Major Business
    Table 22. Bayer Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 23. Bayer Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Bayer Recent Developments and Future Plans
    Table 25. Secura Bio Company Information, Head Office, and Major Competitors
    Table 26. Secura Bio Major Business
    Table 27. Secura Bio Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 28. Secura Bio Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Secura Bio Recent Developments and Future Plans
    Table 30. Epizyme Company Information, Head Office, and Major Competitors
    Table 31. Epizyme Major Business
    Table 32. Epizyme Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 33. Epizyme Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. Epizyme Recent Developments and Future Plans
    Table 35. Eisai Company Information, Head Office, and Major Competitors
    Table 36. Eisai Major Business
    Table 37. Eisai Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 38. Eisai Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. Eisai Recent Developments and Future Plans
    Table 40. Acrotech Biopharma Company Information, Head Office, and Major Competitors
    Table 41. Acrotech Biopharma Major Business
    Table 42. Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 43. Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. Acrotech Biopharma Recent Developments and Future Plans
    Table 45. Teva Company Information, Head Office, and Major Competitors
    Table 46. Teva Major Business
    Table 47. Teva Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 48. Teva Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. Teva Recent Developments and Future Plans
    Table 50. Eagle Pharmaceuticals Company Information, Head Office, and Major Competitors
    Table 51. Eagle Pharmaceuticals Major Business
    Table 52. Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 53. Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. Eagle Pharmaceuticals Recent Developments and Future Plans
    Table 55. MundiPharma Company Information, Head Office, and Major Competitors
    Table 56. MundiPharma Major Business
    Table 57. MundiPharma Non-Hodgkin's Lymphoma Drug Product and Solutions
    Table 58. MundiPharma Non-Hodgkin's Lymphoma Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 59. MundiPharma Recent Developments and Future Plans
    Table 60. Global Non-Hodgkin's Lymphoma Drug Revenue (USD Million) by Players (2018-2023)
    Table 61. Global Non-Hodgkin's Lymphoma Drug Revenue Share by Players (2018-2023)
    Table 62. Breakdown of Non-Hodgkin's Lymphoma Drug by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 63. Market Position of Players in Non-Hodgkin's Lymphoma Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 64. Head Office of Key Non-Hodgkin's Lymphoma Drug Players
    Table 65. Non-Hodgkin's Lymphoma Drug Market: Company Product Type Footprint
    Table 66. Non-Hodgkin's Lymphoma Drug Market: Company Product Application Footprint
    Table 67. Non-Hodgkin's Lymphoma Drug New Market Entrants and Barriers to Market Entry
    Table 68. Non-Hodgkin's Lymphoma Drug Mergers, Acquisition, Agreements, and Collaborations
    Table 69. Global Non-Hodgkin's Lymphoma Drug Consumption Value (USD Million) by Type (2018-2023)
    Table 70. Global Non-Hodgkin's Lymphoma Drug Consumption Value Share by Type (2018-2023)
    Table 71. Global Non-Hodgkin's Lymphoma Drug Consumption Value Forecast by Type (2024-2029)
    Table 72. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2023)
    Table 73. Global Non-Hodgkin's Lymphoma Drug Consumption Value Forecast by Application (2024-2029)
    Table 74. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 75. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 76. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 77. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 78. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 79. North America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 80. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 81. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 82. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 83. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 84. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 85. Europe Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 86. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 87. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 88. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 89. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 90. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 91. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 92. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 93. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 94. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 95. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 96. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 97. South America Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 98. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 99. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 100. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 101. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 102. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 103. Middle East & Africa Non-Hodgkin's Lymphoma Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 104. Non-Hodgkin's Lymphoma Drug Raw Material
    Table 105. Key Suppliers of Non-Hodgkin's Lymphoma Drug Raw Materials
List of Figures
    Figure 1. Non-Hodgkin's Lymphoma Drug Picture
    Figure 2. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type in 2022
    Figure 4. Oral
    Figure 5. Injection
    Figure 6. Global Non-Hodgkin's Lymphoma Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 7. Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application in 2022
    Figure 8. Hospital Picture
    Figure 9. Retail Pharmacy Picture
    Figure 10. Other Picture
    Figure 11. Global Non-Hodgkin's Lymphoma Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 12. Global Non-Hodgkin's Lymphoma Drug Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 13. Global Market Non-Hodgkin's Lymphoma Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 14. Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Region (2018-2029)
    Figure 15. Global Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Region in 2022
    Figure 16. North America Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 17. Europe Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 18. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 19. South America Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 20. Middle East and Africa Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 21. Global Non-Hodgkin's Lymphoma Drug Revenue Share by Players in 2022
    Figure 22. Non-Hodgkin's Lymphoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 23. Global Top 3 Players Non-Hodgkin's Lymphoma Drug Market Share in 2022
    Figure 24. Global Top 6 Players Non-Hodgkin's Lymphoma Drug Market Share in 2022
    Figure 25. Global Non-Hodgkin's Lymphoma Drug Consumption Value Share by Type (2018-2023)
    Figure 26. Global Non-Hodgkin's Lymphoma Drug Market Share Forecast by Type (2024-2029)
    Figure 27. Global Non-Hodgkin's Lymphoma Drug Consumption Value Share by Application (2018-2023)
    Figure 28. Global Non-Hodgkin's Lymphoma Drug Market Share Forecast by Application (2024-2029)
    Figure 29. North America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2018-2029)
    Figure 30. North America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2018-2029)
    Figure 31. North America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Country (2018-2029)
    Figure 32. United States Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 33. Canada Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 34. Mexico Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 35. Europe Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2018-2029)
    Figure 36. Europe Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2018-2029)
    Figure 37. Europe Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Country (2018-2029)
    Figure 38. Germany Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 39. France Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 40. United Kingdom Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 41. Russia Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 42. Italy Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 43. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2018-2029)
    Figure 44. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2018-2029)
    Figure 45. Asia-Pacific Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Region (2018-2029)
    Figure 46. China Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 47. Japan Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 48. South Korea Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 49. India Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 50. Southeast Asia Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 51. Australia Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 52. South America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2018-2029)
    Figure 53. South America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2018-2029)
    Figure 54. South America Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Country (2018-2029)
    Figure 55. Brazil Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 56. Argentina Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 57. Middle East and Africa Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Type (2018-2029)
    Figure 58. Middle East and Africa Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Application (2018-2029)
    Figure 59. Middle East and Africa Non-Hodgkin's Lymphoma Drug Consumption Value Market Share by Country (2018-2029)
    Figure 60. Turkey Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 61. Saudi Arabia Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 62. UAE Non-Hodgkin's Lymphoma Drug Consumption Value (2018-2029) & (USD Million)
    Figure 63. Non-Hodgkin's Lymphoma Drug Market Drivers
    Figure 64. Non-Hodgkin's Lymphoma Drug Market Restraints
    Figure 65. Non-Hodgkin's Lymphoma Drug Market Trends
    Figure 66. Porters Five Forces Analysis
    Figure 67. Manufacturing Cost Structure Analysis of Non-Hodgkin's Lymphoma Drug in 2022
    Figure 68. Manufacturing Process Analysis of Non-Hodgkin's Lymphoma Drug
    Figure 69. Non-Hodgkin's Lymphoma Drug Industrial Chain
    Figure 70. Methodology
    Figure 71. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Roche
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma

Related Reports

Global Non-Hodgkin's Lymphoma Drug Supply, Demand and Key Producers, 2023-2029

Global Non-Hodgkin's Lymphoma Drug Supply, Demand and Key Producers, 2023-2029

date 25 Feb 2023

date Pharma & Healthcare

The global Non-Hodgkin's Lymphoma Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Non-Hodgkin's Lymphoma Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Non-Hodgkin's Lymphoma Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 09 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Non-Hodgkin's Lymphoma Drug market size was valued at USD 8119.4 million in 2023 and is forecast to a readjusted size of USD 12940 million by 2030 with a CAGR of 6.9% during review period.

Global Non-Hodgkin's Lymphoma Drug Supply, Demand and Key Producers, 2024-2030

Global Non-Hodgkin's Lymphoma Drug Supply, Demand and Key Producers, 2024-2030

date 18 Feb 2024

date Pharma & Healthcare

The global Non-Hodgkin's Lymphoma Drug market size is expected to reach $ 12940 million by 2030, rising at a market growth of 6.9% CAGR during the forecast period (2024-2030).

Product Tags

Non-Hodgkin's Lymphoma Drug

B-Cell Non-Hodgkin's Lymphoma Drug

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>